Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

ConditionsMultiple Myeloma, Relapsed Multiple Myeloma (MM)

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age19+

SponsorSung-Soo Park

About this trial

This is a non-interventional observational study aiming to evaluate the quality of life, efficacy, and safety of advanced immuno-oncology agents versus conventional immuno-oncology therapies in patients with relapsed or refractory multiple myeloma. A total of 174 participants are expected to be enrolled in this study.

The study consists of three parts:

Part 1 is the screening and enrollment phase, during which inclusion and exclusion criteria will be assessed for individuals who have agreed to participate in the study. Eligible participants will be enrolled, and data will be collected on their prioritized treatment value criteria.

Part 2 is the treatment phase, during which participants will receive either conventional immuno-oncology therapy or advanced immuno-oncology agents. Participants will visit the site on Day 1 of each treatment cycle to complete patient-reported outcomes (PROs), and efficacy and safety assessments will be conducted.

Part 3 is the end-of-study visit, during which PROs will again be collected, along with final efficacy and safety assessments.

Additionally, for exploratory purposes, bone marrow and peripheral blood samples will be collected from participants at Seoul St. Mary's Hospital who have consented to sample collection and provision during the study period.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male or female aged 19 years or older.

Diagnosed with multiple myeloma and have been previously treated with at least one proteasome inhibitor, one immunomodulatory drug, and one monoclonal antibody treatment (i.e., exposed to all three classes of immunotherapy agents).

Diagnosed with relapsed or refractory multiple myeloma between the IRB approval date and December 2025, and scheduled to start treatment with either advanced immuno-oncology agents or conventional immuno-oncology agents within one month from screening.

Provided written informed consent after receiving detailed explanation about the study and voluntarily agreed to participate and comply with study requirements.

Disqualifiers

Those who do not agree to participate in the study.

Patients diagnosed with plasma cell disorders other than multiple myeloma (e.g., lymphoma, POEMS syndrome).

Individuals unable to read and understand documents written in Korean.

Trial population

Patients will be selected from Seoul St. Mary hospital and Yeoido St. Mary hospital

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Bispecific antibody
Drug
It uses a dual targeting mechanism to enhance specificity and immune activation. It is an off-the-shelf treatment, and doesn't require a manufacturing process of patient cells.
Antibody-Drug Conjugate
Drug
It is a targeted therapy consisting of a monoclonal antibody linked to a cytotoxic drug. The antibody binds to a specific antigen on cancer cells, delivering the cytotoxic agent directly to the tumor, minimizing systemic toxicity.
Monoclonal antibody
Drug
Monoclonal antibodies are lab-engineered antibodies that target specific antigens expressed on cancer cells. These commonly target CD20 (rituximab or obinutuzumab) to mediate immune destruction.
Proteasome Inhibitor
Drug
It blocks the activity of proteasomes, which role is degrading damaged proteins. This disruption induces apoptosis in cancer cells. Common agents include bortezomib and carfilzomib.
IMiD treatment
Drug
Immune modulatory drugs modulate the immune response by enhancing T-cell and NK cell activty to disrupt tumor progression. Common drugs include lenalidomide and thalidomide.
CAR-T Therapy
Drug
It uses the patient's own T cells, and requires a manufacturing process to modify and expand T cells before infusion. It directly targets B cell specific antigens, such as CD19 or CD20.

Treatment groups

174 Participants

are divided into 2 treatment groups

Group A: Advanced Immuno-oncology Therapy Group2 interventions

Group B: Conventional Immuno-oncology Therapy Group4 interventions

Trial outcomes

Primary outcomes

Quality of Lfe

Quality of life is assessed using validated patient-reported outcome (PRO) questionnaires at baseline and regular intervals during treatment.

Time frame

From treatment initiation up to 12 months

Secondary outcomes

Treatment Efficacy and Survival Outcomes

Treatment Efficacy will be assessed by objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). ORR will be reported as the percentage of participants with complete or partial response per IMWG criteria, based on clinical and imaging assessments. PFS and OS will be measured in months as time-to-event outcomes. Survival Outcomes will be evaluated by the number of participants with adverse events (AEs) and serious adverse events (SAEs), graded using CTCAE. Laboratory safety will be assessed by the number of participants with CTCAE-defined lab abnormalities.

Time frame

From treatment initiation up to 12 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sung-Soo Park

Lead sponsor

Seoul St. Mary's Hospital

Sponsor institution

Eunpyeong St. Mary's Hospital

Collaborator

Source ClinicalTrials.gov

Apply now